in past times several years, the UK has witnessed a revolution in clinical excess weight‑reduction treatments — from the introduction of semaglutide (Wegovy®) towards the expanding attractiveness of tirzepatide (Mounjaro®). Now, Yet another title is drawing consideration in equally medical and pu